AAPGAscentage Pharma Group Inc.Running, no new patients
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Unresectable or Metastatic Melanoma or Advanced Solid Tumors · Melanoma · Uveal Melanoma · P53 Mutation · MDM2 Gene Mutation · Cutaneous Melanoma · Mucosal Melanoma · Malignant Peripheral Nerve Sheath Tumors (MPNST)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 230 (planned)
- Started
- Aug 29, 2018
- Main results expected
- Dec 30, 2025
- Fully finished
- Dec 30, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Maximum Tolerated Dose
Measured over: 21 days
Recommended Phase II Dose
Measured over: 21 days
Overall Response Rate
Measured over: up to 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03611868 · record last updated 2025-08-07 · checked 2026-11-09 15:47 UTC